id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10173 R37179 |
Blotière (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.93 [0.08;47.52] C excluded (control group) |
0/517 1/2,997 | 1 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10048 R36430 |
Blotière (Topiramate) (Controls unexposed NOS) (Mixed indications), 2019 | Spina bifida | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.94 [0.18;47.19] C | 0/517 616/1,875,733 | 616 | 517 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8594 R28607 |
Veiby (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
17.53 [0.34;893.01] C excluded (control group) |
0/48 0/833 | 0 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8596 R28617 |
Veiby (Topiramate) (Controls unexposed, sick) (Mixed indications), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 11.34 [0.58;222.54] C | 0/48 3/3,773 | 3 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 5.51 [0.72;41.94] | 619 | 565 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed NOS) (Mixed indications; 2: Topiramate) (Controls unexposed, sick) (Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8594, 10173